Company: DHR
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0000313616-25-000088
Chunk: 115

Company: DANAHER CORP /DE/
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 2
Chunk 115
---
 profit margin comparisons were favorably impacted by:

•Higher 2025 core sales, the impact of product mix and improvements in the segment’s operational and administrative cost structure, net of the impact of currency exchange rates - 700 basis points

First quarter 2025 vs. first quarter 2024 operating profit margin comparisons were unfavorably impacted by:

•First quarter 2025 impairment charge related to a facility in the Biotechnology segment - 90 basis points

Depreciation and amortization of intangible assets as a percentage of sales decreased during the three-month period ended March 28, 2025 as compared to the comparable period of 2024, primarily as a result of the increase in sales.

LIFE SCIENCES

The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies.  Additionally, the segment provides products and consumables used to filter and remove contaminants from a variety of liquids and gases in many end-market applications.

Life Sciences Selected Financial Data 

 Three-Month Period Ended($ in millions)March 28, 2025March 29, 2024Sales$1,680 $1,745 Operating profit201 235 Depreciation45 38 Amortization of intangible assets149 141 Operating profit as a % of sales12.0 %13.5 %Depreciation as a % of sales2.7 %2.2 %Amortization as a % of sales8.9 %8.1 %

Sales Decline and Core Sales Decline

% Change Three-Month Period Ended March 28, 2025 vs. Comparable 2024 PeriodTotal sales decline (GAAP)(3.5)%Impact of:Acquisitions(2.0)%Currency exchange rates 1.5 %Core sales decline (non-GAAP)(4.0)%

25

Price increases in the segment did not have a significant impact on the change in sales on a year-over-year basis during the three-month period ended March 28, 2025 and are reflected as a component of core sales above.

Total segment sales decreased 3.5% during the three-month period ended March 28, 202